Skip to main content

Table 1 Baseline Characteristics and Demographics

From: Construct validation of patient global impression of severity (PGI-S) and improvement (PGI-I) questionnaires in the treatment of men with lower urinary tract symptoms secondary to benign prostatic hyperplasia

Baseline Characteristics

Statistics

Total number of randomized patients, N

1694

Age, mean (SD)

63.1 (8.2)

Peak urine flow rate (Qmax)

 

  Mild (Qmax > 15 ml/s), n (%)

11 (0.7%)

  Moderate (Qmax 10–15 ml/s), n (%)

837 (50.7%)

  Severe (Qmax < 10 ml/s), n (%)

802 (48.6%)

PSA (mg/L), mean (SD)

1.8 (1.6)

PVR (mL), mean (SD)

38.1 (42.0)

LUTS Severity

 

  Moderate (IPSS 8–19), n (%)

1090 (64.4%)

  Severe (IPSS >= 20), n (%)

603 (35.6%)

Race/Ethinity

 

  Asian, n (%)

763(45.0%)

  Caucasian, n (%)

861(50.8%)

  Hispanic Caucasian, n (%)

164 (9.7%)

  Non-Hispanic Caucasian, n (%)

697 (41.1%)

  Other Race, n (%)

70 (4.1%)

  1. SD: standard deviation; n: number of patients; PSA: Prostate-specific antigen; PVR: post-void residual urine volume; LUTS: Lower Urinary Tract Symptoms; Asian: from the 2 studies conducted in Asia; Caucasian/Other race: from the 2 studies conducted outside Asia. Values are from V1-V2, before enrolled into the single-blind placebo run in period.